About Boundless Bio Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://boundlessbio.com/
Frequently Asked Questions
What is the 52-week range for BOLD?
The 52-week high is $3.1636 and the 52-week low is $0.9612.
What is the P/E ratio for BOLD?
The P/E ratio data is currently unavailable.
What is the dividend yield for BOLD?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -70.89%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.27.
Analyst Recommendation Trends
Wall Street analyst consensus for BOLD over the last few months:
Latest BOLD News
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028â2029, cash runway/dilution risks, valuation vs peersâread now.
Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer
Industry veteran brings more than two decades of oncology drug discovery leadership to advance Callio's dual-payload ADC pipelineSAN DIEGO and SEATTLE and SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics (“Callio” or “the Company”), a global, clinical-stage biotechnology company advancing dual-payload antibody-drug conjugates (ADCs) as the next frontier of rationally designed targeted cancer therapy, today announced the appointment of Chris Hassig, PhD, as Chief Scientific Offic
Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer
Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancer Piers Ingram, PhD, Co-Founder, transitions to Senior Advisor and continues to serve on the Board of Directors; Jerome Boyd-Kirkup, PhD, founding Chief Scientific Officer, transitions to Senior Scientific Advisor SAN DIEGO and SEATTLE and SINGAPORE, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics (“Callio” or “the Company”), a clinical-stage
Callio Therapeutics Appoints Zachary Hornby As CEO
Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancerPiers Ingram, PhD, Co-Founder, transitions to Senior Advisor and
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-26 | TANG KEVIN | -18,300 | $2.97 | $54,351 |
| 2026-07-21 | TANG KEVIN | +2,975 | $2.44 | $7,259 |
| 2026-07-20 | TANG KEVIN | +1,623 | $2.44 | $3,960 |
| 2026-07-17 | TANG KEVIN | +265 | $2.44 | $647 |
| 2026-07-16 | TANG KEVIN | +18,491 | $2.44 | $45,118 |
| 2026-07-15 | TANG KEVIN | +1,600 | $2.44 | $3,904 |
| 2026-07-14 | TANG KEVIN | +43,878 | $2.43 | $106,624 |
| 2026-07-13 | TANG KEVIN | +48,211 | $2.42 | $116,671 |
| 2026-07-10 | TANG KEVIN | +43,367 | $2.43 | $105,382 |
| 2026-07-09 | TANG KEVIN | +7 | $2.48 | $17 |
| 2026-07-08 | TANG KEVIN | +14,338 | $2.46 | $35,271 |
| 2026-07-07 | TANG KEVIN | +15,810 | $2.48 | $39,209 |
| 2026-07-06 | TANG KEVIN | +27,062 | $2.49 | $67,384 |
| 2026-07-02 | TANG KEVIN | +9,821 | $2.49 | $24,454 |
| 2026-07-01 | ARCH Venture Fund IX, L.P. | -16,000 | - | - |
| 2026-07-01 | ARCH Venture Fund IX, L.P. | -16,000 | $2.49 | $39,840 |
| 2026-07-01 | ARCH Venture Fund IX, L.P. | +16,000 | $1.03 | $16,480 |
| 2026-07-01 | CRANDELL KEITH | -16,000 | - | - |
| 2026-07-01 | CRANDELL KEITH | -16,000 | $2.49 | $39,840 |
| 2026-07-01 | CRANDELL KEITH | +16,000 | $1.03 | $16,480 |
| 2026-07-01 | TANG KEVIN | +71,612 | $2.49 | $178,314 |
| 2026-06-30 | TANG KEVIN | +100 | $2.5 | $250 |
| 2026-06-30 | TANG KEVIN | +25,930 | $2.54 | $65,862 |
| 2026-06-15 | Whiting Nancy | +32,000 | - | - |
| 2026-06-15 | Christensen James | +32,000 | - | - |
| 2026-06-15 | Lew Jennifer | +32,000 | - | - |
| 2026-06-15 | Lim Jonathan E | +48,000 | - | - |
| 2026-01-23 | Doebele Robert | +230,000 | - | - |
| 2026-01-23 | Oien Jessica | +220,000 | - | - |
| 2026-01-23 | Hassig Christian | +230,000 | - | - |
| 2026-01-23 | Hornby Zachary | +600,000 | - | - |
| 2026-01-23 | HINKLE DAVID A | +140,000 | - | - |